Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
San Francisco, California–(Newsfile Corp. – December 25, 2024) – On December 9, 2024, a few months after filing a public offering in September 2024, BioAge Labs, Inc. ((NASDAQ: BIOA) made a surprise announcement that it is suspending a Phase 2 study for its lead product, azelaprag, which is intended to treat metabolic diseases such as obesity.
Hagens Berman has opened research and encourages BioAge investors who bought shares in the company’s IPO or in the open market and have lost a lot to give your losses now.
Visit: www.hbsslaw.com/investor-fraud/bioa
Contact The Firm Now: BIOA@hbsslaw.com
844-916-0895
Research by BioAge Labs, Inc. (BIOA):
The investigation focused on the accuracy of BioAge’s statements about safety data and other issues related to azelaprag, which the company said in its IPO filings “was well tolerated in 265 people in eight Phase 1 trials .”
BioAge’s revelations were questioned after the market closed on December 6, 2024, when the company announced the suspension of the STRIDES Phase 2 clinical trial testing azelaprag in combination with tirzepatide for the treatment of obesity. BioAge said that transaminitis of the liver has been seen in patients receiving azelaprag.
This news has reduced the price of BioAge shares by less than 80% on December 9, 2024.
“We are focused on whether BioAge was transparent with investors about the safety status of azelaprag prior to the December 6 announcement,” said Reed Kathrein, the partner at Hagens Berman who is leading the investigation.
If you have invested in BioAge and have a large loss, or have information that can help the company’s investigation, submit your loss now »
If you would like information and answers to frequently asked questions about BioAge research, read more »
Callers: Individuals with non-public information about BioAge should consider their options to assist in an investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers can receive rewards of up to 30 percent of any successful settlement made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email BIOA@hbsslaw.com.
###
About Hagens Berman
Hagens Berman is a sophisticated global plaintiffs’ rights litigation firm focused on corporate liability. The firm has a strong practice and represents investors as well as investors, employees, customers and others in a position to achieve real results for those injured by corporate negligence and other wrongdoing. The Hagens Berman Group has earned over $2.9 billion in this area of law. More information about the firm and its achievements can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
To view the source version of this release, please visit https://www.newsfilecorp.com/release/235182
